Closely-held CRISPR Therapeutics has appointed Marc Becker as CFO to further support the company’s efforts to develop game-changing drugs derived from its proprietary CRISPR-Cas9 gene-editing technology platform.
Mr. Becker is a seasoned executive who brings more than 20 years of experience in commercial, operational and corporate finance and a deep understanding of the global biopharmaceutical industry.
Mr. Becker most recently was CFO and senior VP of rEVO Biologics, where he led the finance team in raising private and public capital, outlined the market opportunity for the company and managed its governance and SEC compliance through S-1 filing and IPO road show.
“Marc’s extensive network and proven track record to establish internal controls will be vital as we continue to engage in key strategic ventures to support the discovery, development and commercialization of new breakthrough therapeutics,” CEO, Dr. Rodger Novak, said in a statement.
Mr. Becker said he was excited to join the CRISPR’s leadership team as the company’s growth accelerates with the introduction of strategic partnerships and ventures. “Our technology is truly revolutionary and I’m delighted to be part of the team that will enable the development of life-changing medicines.”
